Last reviewed · How we verify

Sulfadoxine-pyrimethamine used for IPTi — Competitive Intelligence Brief

Sulfadoxine-pyrimethamine used for IPTi (Sulfadoxine-pyrimethamine used for IPTi) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimalarial combination. Area: Infectious Disease.

phase 3 Antifolate antimalarial combination Dihydropteroate synthase; Dihydrofolate reductase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sulfadoxine-pyrimethamine used for IPTi (Sulfadoxine-pyrimethamine used for IPTi) — Swiss Tropical & Public Health Institute. Sulfadoxine-pyrimethamine is a fixed-dose combination of two antifolate drugs that inhibits dihydrofolate reductase and dihydropteroate synthase, blocking folate synthesis in malaria parasites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sulfadoxine-pyrimethamine used for IPTi TARGET Sulfadoxine-pyrimethamine used for IPTi Swiss Tropical & Public Health Institute phase 3 Antifolate antimalarial combination Dihydropteroate synthase; Dihydrofolate reductase
Sulfamethoxazole-Trimethoprim Sulfamethoxazole-Trimethoprim National Institute of Allergy and Infectious Diseases (NIAID) marketed Sulfonamide-dihydrofolate reductase inhibitor combination Dihydropteroate synthase; Dihydrofolate reductase
Sulfamethoxazole Trimethoprim Combination Sulfamethoxazole Trimethoprim Combination Baylor Research Institute marketed Sulfonamide-dihydrofolate reductase inhibitor combination Dihydropteroate synthase; Dihydrofolate reductase
IPTp-SP IPTp-SP Kenya Medical Research Institute marketed Antifolate antimalarial combination Dihydrofolate reductase (DHFR)
Intermittent preventive treatment:sulphadoxine-pyrimethamine Intermittent preventive treatment:sulphadoxine-pyrimethamine London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination Dihydropteroate synthase and dihydrofolate reductase
sulfadoxine pyrimethamine plus piperaquine sulfadoxine pyrimethamine plus piperaquine London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination with quinoline antimalarial Plasmodium dihydrofolate reductase, dihydropteroate synthase, and parasite mitochondria
sulfadoxine-pyrimethamine and chlorproguanil-dapsone sulfadoxine-pyrimethamine and chlorproguanil-dapsone London School of Hygiene and Tropical Medicine phase 3 Antifolate antimalarial combination Dihydrofolate reductase; dihydropteroate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimalarial combination class)

  1. London School of Hygiene and Tropical Medicine · 4 drugs in this class
  2. Kenya Medical Research Institute · 1 drug in this class
  3. Swiss Tropical & Public Health Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sulfadoxine-pyrimethamine used for IPTi — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfadoxine-pyrimethamine-used-for-ipti. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: